Doubts Raised Regarding AstraZeneca’s Most Recent Vaccine Trial Data

Doubts Raised Regarding AstraZeneca’s Most Recent Vaccine Trial Data

As TrialSite has chronicled, AstraZeneca has struggled during the pandemic to keep open, transparent communications as an expectation. In “On Again Off Again: the Rollercoaster Associated with AstraZeneca,” the at times opaque and elusive elements associated with AZD1222 vaccine trial compound to what many consider an impact to the overall brand. Now it turns out, there is more to the story. AstraZeneca may have released outdated information on its latest COVID-19 vaccine trial, giving an “incomplete” picture of its efficacy, a leading U.S. health agency said on Tuesday, casting even more doubt on the shot’s potential U.S. rollout and plunging its developers, once again, into controversy. This is truly unfortunate. This vaccine shows enormous potential as it can be delivered around the world at compelling price points. Put another way, the world truly needs a vaccine such as this one, and the hope is that concepts such as transparency and accountability are embraced, even when circumstances are tough. 

The surprise public rebuke from federal health officials comes just one day after interim data from the drugmaker showed better-than-expected results from the U.S. trial. Th...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee